ReviewThe Journal of general virology2024
Oropouche Virus: An Emerging Orthobunyavirus.
Review in The Journal of general virology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Vector competence for Oropouche virus: A systematic review of pre-2024 experiments.PLoS neglected tropical diseases · 2025Pooled it
- Oropouche virus infection: clinical spectrum, geographic expansion, and emerging maternal-fetal implications.Infection · 2026Review
- Comparative analysis of host responses to Oropouche viruses in placental cell infection models.PLoS neglected tropical diseases · 2026Article
- In silico pharmacological evaluation of a multi-epitope vaccine candidate targeting the G1 and G2 glycoproteins of Oropouche virus via TLR3 interaction.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Rift Valley fever virus infects trophoblast cell lines in an LRP1-dependent manner.The Journal of general virology · 2026Article
- Review
- Article
- Mutation of a conserved lysine in the RdRp fingers domain broadly attenuates orthobunyaviruses.Communications biology · 2026Article
- Antiviral Mechanisms of Justicidin B and Tuberculatin fromACS omega · 2026Article
- Structural basis for RNA synthesis and inhibition of the orthobunyavirus polymerase.Nature communications · 2026Article
- Conserved pathogenesis of ancestral and contemporary Oropouche virus strains in a murine pregnancy model.Nature communications · 2026Article
- Transmission dynamics of Oropouche virus in Latin America and the Caribbean.Nature medicine · 2026Article
- Oropouche virus infects human neural progenitor cells and alters the growth of brain organoids.iScience · 2026Article
- Oropouche Virus (OROV) Vaccine Development for Vulnerable Populations: Epidemiological Context, Challenges and Future Directions.Vaccines · 2026Review
- Conserved non-coding RNA motifs influence the neuropathogenicity of Simbuviruses: Molecular dissection in the Schmallenberg virus model.PLoS pathogens · 2026Article
- Article
- Enhanced virulence and neuroinvasion of contemporaryFrontiers in microbiology · 2026Article
- Risk Assessment of Oropouche Virus Transmission by Mosquitoes in Europe.The Journal of infectious diseases · 2025Article
- Oropouche virus: molecular virological characteristics and research progress of a neglected arbovirus.Virology journal · 2025Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
On 2 February 2024, the Pan American Health Organization/World Health Organization issued an epidemiological alert on rising Oropouche virus (OROV) infections in South America. By 3 August 2024, this alert level had escalated from medium to high. OROV has been a public health concern in Central and South America since its emergence in Brazil in the 1960s. However, the 2024 outbreak marks a turning point, with the sustained transmission in non-endemic regions of Brazil, local transmission in Cuba, two fatalities and several cases of vertical transmission. As of the end of August 2024, 9852 OROV cases have been confirmed. The 2024 OROV outbreak underscores critical gaps in our understanding of OROV pathogenesis and highlights the urgent need for antivirals and vaccines. This review aims to provide a concise overview of OROV, a neglected orthobunyavirus.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.